PURE Bioscience (OTCMKTS:PURE) Announces Earnings Results

PURE Bioscience (OTCMKTS:PURE) released its quarterly earnings results on Monday. The company reported ($0.01) earnings per share for the quarter, Zacks reports. The company had revenue of $0.39 million during the quarter.

PURE Bioscience Price Performance

Shares of PURE Bioscience stock opened at $0.06 on Wednesday. The business has a 50 day simple moving average of $0.07 and a two-hundred day simple moving average of $0.08. PURE Bioscience has a 12 month low of $0.05 and a 12 month high of $0.16. The stock has a market capitalization of $6.70 million, a P/E ratio of -1.50 and a beta of 0.35.

About PURE Bioscience

PURE Bioscience, Inc develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.